QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=345F3C3E31C12C444C4BFB6C7444F45F;jsessionid=BD9211D0409253AA8F0D3B430F1ADC06;jsessionid=FA979FF6DE873EBD7E5AC2E0DD2DEB1A;jsessionid=E1BB80C09086475ADB27119A3CDD32ED;jsessionid=4043DD0DD7500E2D9DCA95203B99031C;jsessionid=8096AA3D0A7239BC68D0631183BF77A3;jsessionid=8C6CB774AF28B38BFACDA266B4A04CEF (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
4. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.
5. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=345F3C3E31C12C444C4BFB6C7444F45F;jsessionid=BD9211D0409253AA8F0D3B430F1ADC06;jsessionid=FA979FF6DE873EBD7E5AC2E0DD2DEB1A;jsessionid=E1BB80C09086475ADB27119A3CDD32ED;jsessionid=4043DD0DD7500E2D9DCA95203B99031C;jsessionid=8096AA3D0A7239BC68D0631183BF77A3;jsessionid=8C6CB774AF28B38BFACDA266B4A04CEF